Leadership Team

Dr. Carl Schwartz
CHAIRMAN & CEO

Dr. Schwartz holds BA and DDS degrees from the University of Detroit and grew a single dental practice into 14 offices by the time he left dentistry to join a family business in 1988. As CEO of Plastics Research Corporation, a specialty manufacturer of structural foam molding, he led company growth from $2 million in revenues and 20 employees to become the largest manufacturer of structural foam molding products under one roof in the country with more than $60 million in revenues and 300 employees. From a board appointment to Skyline Medical in 2016, Dr. Schwartz began making his vision of personalized medicine a reality. TumorGenesis was formed as a subsidiary in 2018 and Helomics was acquired in 2019. The synergistic and complementary companies form the basis of Predictive Oncology and represent a paradigm shift in in the predictive models needed for effective precision medicine.

Bob Myers
CHIEF FINANCIAL OFFICER

Mr. Myers was appointed CFO and Secretary in 2012. He has over 30 years experience in multiple industries focusing on medical device, service and manufacturing. He has spent much of his career as a CFO and Controller. A public accountant with the international firm of Laventhol & Horwath, he was CFO of Disetronic and Corporate Controller for Diametric Medical Devices. He has also held executive positions with American Express, Capitol Distributions and International Creative Management. Mr. Myers has an MBA in Finance from Adelphi University and a BBA in Public Accounting from Hofstra University.

Gerald Vardzel
PRESIDENT, HELOMICS

Mr. Vardzel has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Amelia Warner
INTERIM CHIEF OPERATING OFFICER, HELOMICS

Dr. Amelia Warner founded Global Specimen Solutions, Inc. in 2013 with the vision of radically improving translational science through powerful new pipeline data management analytics. Prior to GSS, Amelia served as CEO, President and Director of the Board for Gentris Corporation, where she led a financial and operational turnaround resulting in the successful sale of Gentris to a public company. Amelia served as the Head of Clinical Pharmacogenomics and Clinical Specimen Management for Merck Research Laboratories (MRL). She oversaw all clinical pharmacogenomics projects, as well as policies and procedures for biosample collection and storage for clinical trial samples; she also served as the MRL Pharmacogenomics Expert for the Translational Science Research Network. She was the MRL Key Expert for Global Regulation for Genetic Research and Human Specimen Usage Regulation/Law. She served as Chair of the Industry Pharmacogenomics Working Group (I-PWG) and a PhRMA Representative to ICH E16- Genomic Biomarkers Related to Drug Response. Amelia completed a Residency in Pediatric Pharmacotherapy at St. Jude Children’s Research Hospital and a Fellowship in Clinical Pharmacology/Pharmacogenomics at St. Jude Children’s Research Hospital with William Evans, PharmD. Amelia holds a BS in Biology from Wake Forest University and a PharmD from the University of North Carolina at Chapel Hill.

Dr. Mark Collins
CHIEF INFORMATION OFFICER, HELOMICS

Dr. Collins has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Advisory Board

Paul Kornblith, M.D.
MEDICAL ADVISER TO HELOMICS

Paul Kornblith, M.D., currently serves as the Medical Advisor to Helomics, the Pittsburgh Life Sciences Greenhouse, and the Innovation Institute; as an Adjunct Professor in the School of Health and Rehabilitation at the University of Pittsburgh; and as the Western Pennsylvania Director for Life Sciences PA. A world-renown neurosurgeon, clinician, and clinical cancer researcher, Dr. Kornblith has authored over 150 peer-reviewed publications, 30 textbook chapters, and four textbooks. Dr. Kornblith also served as Vice Chairman of the Department of Neurosurgery at the University of Pittsburgh Medical School and the University of Pittsburgh Medical Center; Professor and Chairman of the Department of Neurosurgery at the Albert Einstein College of Medicine and Montefiore Hospital in New York; Chief of the Surgical Neurology Branch and Interim Clinical Director of the Neurological Institute at the National Institutes of Health in Bethesda, MD; Assistant Professor of Surgery and Director of the Cancer Program Project in the Department of Neurosurgery at Harvard University, and as an Attending Neurosurgeon at the Massachusetts General Hospital in Boston; and Editor-and-Chief of the Journal of Neuro-Oncology. Dr. Kornblith received his B.A. degree from Temple University and his M.D degree from Thomas Jefferson Medical School.

Amelia Wall Warner PharmD, RPh
FOUNDER AND CEO OF GLOBAL SPECIMEN SOLUTIONS, INC

Dr. Amelia Warner founded Global Specimen Solutions, Inc. in 2013 with the vision of radically improving translational science through powerful new pipeline data management analytics. Prior to GSS, Amelia served as CEO, President and Director of the Board for Gentris Corporation, where she led a financial and operational turnaround resulting in the successful sale of Gentris to a public company. Amelia served as the Head of Clinical Pharmacogenomics and Clinical Specimen Management for Merck Research Laboratories (MRL). She oversaw all clinical pharmacogenomics projects, as well as policies and procedures for biosample collection and storage for clinical trial samples; she also served as the MRL Pharmacogenomics Expert for the Translational Science Research Network. She was the MRL Key Expert for Global Regulation for Genetic Research and Human Specimen Usage Regulation/Law. She served as Chair of the Industry Pharmacogenomics Working Group (I-PWG) and a PhRMA Representative to ICH E16- Genomic Biomarkers Related to Drug Response. Amelia completed a Residency in Pediatric Pharmacotherapy at St. Jude Children’s Research Hospital and a Fellowship in Clinical Pharmacology/Pharmacogenomics at St. Jude Children’s Research Hospital with William Evans, PharmD. Amelia holds a BS in Biology from Wake Forest University and a PharmD from the University of North Carolina at Chapel Hill.

Mark Malandro, Ph.D, CLP, RTTP
VICE PRESIDENT OF OPERATIONS FOR SCIENCES, CHAN ZUCKERBERG SCIENCE INITIATIVE

Marc Malandro PhD, CLP, RTTP is currently Vice President of Operations for Science at the Chan Zuckerberg Initiative. Dr. Malandro was the founding director of the Innovation Institute and Vice Chancellor for Technology Management and Commercialization at the University of Pittsburgh. Dr. Malandro was responsible for leading the combination of the Office of Technology Management, the Office of Enterprise Development and the Institute for Entrepreneurial Excellence forming the Pitt Innovation Institute in 2013. Prior to The University of Pittsburgh, Dr. Malandro, who has a doctoral degree in biochemistry and molecular biology from the University of Florida, co-founded Sagres Discovery, a California-based systems biology company focused on the understanding of the molecular basis of cancer.

Prof. Robert Murphy, Ph.D
HEAD, COMPUTATIONAL BIOLOGY DEPARTMENT CARNEGIE MELLON UNIVERSITY

Robert F. Murphy is the Ray and Stephanie Lane Professor of Computational Biology and Head of the Computational Biology Department (formerly the Ray and Stephanie Lane Center for Computational Biology) in the School of Computer Science at Carnegie Mellon University. He also is Professor of Biological Sciences, Biomedical Engineering, and Machine Learning, and was a founding director (with Ivet Bahar) of the Joint Carnegie Mellon University-University of Pittsburgh Ph.D. Program in Computational Biology. He is also Honorary Professor of Biology at the Albert Ludwig University of Freiburg, Germany, was named as the first External Senior Fellow of the School of Life Sciences in the Freiburg Institute for Advanced Studies, and was the recipient of an Alexander von Humboldt Foundation Senior Research Award. He is a Fellow of the American Institute for Medical and Biological Engineering and served as President of the International Society for Advancement of Cytometry. He was the first full-term chair of the Biodata Management and Analysis Study Section of the National Institutes of Health, and was a member of the National Advisory General Medical Sciences Council, and the National Institutes of Health Council of Councils. Dr. Murphy has received research grants from the National Institutes of Health, the National Science Foundation, the American Cancer Society, the American Heart Association, the Arthritis Foundation, and the Rockefeller Brothers Fund. He has co-edited two books and three special journal issues on cell imaging, and has published over 200 research papers. Dr. Murphy received an A.B. in Biochemistry from Columbia College and a Ph.D. in Biochemistry from the California Institute of Technology.

Wordpress Social Share Plugin powered by Ultimatelysocial